Inside the FDA’s National Priority Voucher Program 

In a recent article published by Drug Discovery News examining the FDA’s new National Priority Voucher program, Project Farma leaders Anshul Mangal, Rich Tree, and Shelley Preslar share expert perspective on what accelerated drug review timelines could mean for the industry. Their insights touch on the implications for sponsors, regulators, and manufacturing readiness, highlighting both the potential to advance therapies to patients faster and the importance of maintaining operational rigor to support quality and safety. 

Click here to read, ‘FDA compresses drug review timelines in new national priority initiative’.